Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of ABI-007 Administered Weekly for Three Doses Every 4 Weeks in Patients With Advanced Non-hematologic Malignancies

NCT00046423 is registered in ClinicalTrials.gov with Celgene Corporation as lead sponsor.

NCT NCT00046423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00046423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of ABI-007 Administered Weekly for Three Doses Every 4 Weeks in Patients With Advanced Non-hematologic Malignancies
Lead sponsor
Celgene Corporation
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2000
Completion date
Not reported
Enrollment
20
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastases, neoplasm, neoplasms